Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 May 27

PMID 37243251

Authors

Georgios Schinas

Vasiliki Moustaka

Eleni Polyzou

Maria Panagiota Almyroudi

George Dimopoulos

Karolina Akinosoglou

Affiliations

Soon will be listed here.

Abstract

Cytomegalovirus (CMV) reactivation has been linked to adverse clinical outcomes in critically ill patients, with emerging evidence suggesting a potential connection with severe COVID-19. Mechanisms driving this association may include primary lung injury, amplification of systemic inflammation, and secondary immunosuppression. Diagnostic challenges in detecting and assessing CMV reactivation necessitate a comprehensive approach to improve accuracy and inform treatment decisions. Currently, there is limited evidence on the efficacy and safety of CMV pharmacotherapy in critically ill COVID-19 patients. Although insights from non-COVID-19 critical illness studies suggest a potential role for antiviral treatment or prophylaxis, the risks and benefits must be carefully balanced in this vulnerable patient population. Understanding the pathophysiological role of CMV in the context of COVID-19 and exploring the advantages of antiviral treatment are crucial for optimizing care in critically ill patients. This review provides a comprehensive synthesis of available evidence, emphasizing the need for additional investigation to establish the role of CMV treatment or prophylaxis in the management of severe COVID-19 and to develop a framework for future research on this topic.

Citing Articles

What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients.

Fernandez S, Castro P, Azoulay E Intensive Care Med. 2025; 51(1):39-61.

PMID: 39774866 DOI: 10.1007/s00134-024-07737-5.

Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients' Prognosis.

Frattari A, Polilli E, Timelli L, Spagnuolo F, Fazii P, Parruti G Antibiotics (Basel). 2024; 13(11).

PMID: 39596696 PMC: 11591351. DOI: 10.3390/antibiotics13111001.

Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia.

Shen H, Feng J, Sun C, Huang J, Chen Y, Chen W Ther Adv Respir Dis. 2023; 17:17534666231209150.

PMID: 37949827 PMC: 10640799. DOI: 10.1177/17534666231209150.

References

Talan L, Kalkan I, Altintas N, Yoruk F . Cytomegalovirus Reactivation in Critically-ill COVID-19 Patients. Balkan Med J. 2022; 39(4):301-302. PMC: 9326950. DOI: 10.4274/balkanmedj.galenos.2022.2022-2-2. View

Naendrup J, Garcia Borrega J, Eichenauer D, Shimabukuro-Vornhagen A, Kochanek M, Boll B . Reactivation of EBV and CMV in Severe COVID-19-Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients. J Intensive Care Med. 2021; 37(9):1152-1158. PMC: 9396115. DOI: 10.1177/08850666211053990. View

Taherifard E, Movahed H, Kiani Salmi S, Taherifard A, Abdollahifard S, Taherifard E . Cytomegalovirus coinfection in patients with severe acute respiratory syndrome coronavirus 2 infection: a systematic review of reported cases. Infect Dis (Lond). 2022; 54(8):543-557. DOI: 10.1080/23744235.2022.2070273. View

Papazian L, Jaber S, Hraiech S, Baumstarck K, Cayot-Constantin S, Aissaoui N . Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation. Ann Intensive Care. 2021; 11(1):33. PMC: 7876264. DOI: 10.1186/s13613-020-00793-2. View

Willette A, Willette S, Wang Q, Pappas C, Klinedinst B, Le S . Using machine learning to predict COVID-19 infection and severity risk among 4510 aged adults: a UK Biobank cohort study. Sci Rep. 2022; 12(1):7736. PMC: 9092926. DOI: 10.1038/s41598-022-07307-z. View

Limaye A, Stapleton R, Peng L, Gunn S, Kimball L, Hyzy R . Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial. JAMA. 2017; 318(8):731-740. PMC: 5817487. DOI: 10.1001/jama.2017.10569. View

Chiche L, Forel J, Roch A, Guervilly C, Pauly V, Allardet-Servent J . Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009; 37(6):1850-7. DOI: 10.1097/CCM.0b013e31819ffea6. View

Imlay H, Dasgupta S, Boeckh M, Stapleton R, Rubenfeld G, Chen Y . Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies. J Infect Dis. 2020; 223(12):2108-2112. PMC: 8496661. DOI: 10.1093/infdis/jiaa697. View

Ong D, Klein Klouwenberg P, Verduyn Lunel F, Spitoni C, Frencken J, Dekker H . Cytomegalovirus seroprevalence as a risk factor for poor outcome in acute respiratory distress syndrome*. Crit Care Med. 2014; 43(2):394-400. DOI: 10.1097/CCM.0000000000000712. View

10.

Brantsaeter A, Holberg-Petersen M, Jeansson S, Goplen A, Bruun J . CMV quantitative PCR in the diagnosis of CMV disease in patients with HIV-infection - a retrospective autopsy based study. BMC Infect Dis. 2007; 7:127. PMC: 2194717. DOI: 10.1186/1471-2334-7-127. View

11.

Kuo C, Wang S, Tsai H, Su P, Cia C, Lai C . Invasive pulmonary aspergillosis is associated with cytomegalovirus viremia in critically ill patients - A retrospective cohort study. J Microbiol Immunol Infect. 2021; 55(2):291-299. DOI: 10.1016/j.jmii.2021.03.005. View

12.

Perera M, Greenwood E, Crozier T, Elder E, Schmitt J, Crump C . Human Cytomegalovirus Infection of Epithelial Cells Increases SARS-CoV-2 Superinfection by Upregulating the ACE2 Receptor. J Infect Dis. 2022; 227(4):543-553. PMC: 9927080. DOI: 10.1093/infdis/jiac452. View

13.

Loewendorf A, Arens R, Purton J, Surh C, Benedict C . Dissecting the requirements for maintenance of the CMV-specific memory T-cell pool. Viral Immunol. 2011; 24(4):351-5. PMC: 3154399. DOI: 10.1089/vim.2010.0140. View

14.

De Vlieger G, Meersseman W, Lagrou K, Wouters P, Wilmer A, Peetermans W . Cytomegalovirus serostatus and outcome in nonimmunocompromised critically ill patients. Crit Care Med. 2011; 40(1):36-42. DOI: 10.1097/CCM.0b013e31822b50ae. View

15.

Schoninger S, Dubrovskaya Y, Marsh K, Altshuler D, Prasad P, Louie E . Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection. Open Forum Infect Dis. 2022; 9(7):ofac286. PMC: 9214167. DOI: 10.1093/ofid/ofac286. View

16.

Limaye A, Kirby K, Rubenfeld G, Leisenring W, Bulger E, Neff M . Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008; 300(4):413-22. PMC: 2774501. DOI: 10.1001/jama.300.4.413. View

17.

Frantzeskaki F, Karampi E, Kottaridi C, Alepaki M, Routsi C, Tzanela M . Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers. J Crit Care. 2014; 30(2):276-81. DOI: 10.1016/j.jcrc.2014.10.002. View

18.

Cano P, Han F, Wang H, Fernandez-Vina M, Han X . Cytokine gene polymorphisms affect reactivation of cytomegalovirus in patients with cancer. Cytokine. 2012; 60(2):417-22. DOI: 10.1016/j.cyto.2012.07.018. View

19.

Diggins N, Skalsky R, Hancock M . Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs. Pathogens. 2021; 10(2). PMC: 7918750. DOI: 10.3390/pathogens10020200. View

20.

Niitsu T, Shiroyama T, Hirata H, Noda Y, Adachi Y, Enomoto T . Cytomegalovirus infection in critically ill patients with COVID-19. J Infect. 2021; 83(4):496-522. PMC: 8268671. DOI: 10.1016/j.jinf.2021.07.004. View